(nafarelin acetate)
The diagnosis of central precocious puberty (CPP) must be established before treatment is initiated. Regular monitoring of CPP patients is needed to assess both patient response as well as compliance. This is particularly important during the first 6 to 8 weeks of treatment to assure that suppression of pituitary-gonadal function is rapid. Testing may include LH response to GnRH stimulation and circulating gonadal sex steroid levels. Assessment of growth velocity and bone age velocity should begin within 3 to 6 months of treatment initiation.
Some patients may not show suppression of the pituitary-gonadal axis by clinical and/or biochemical parameters. This may be due to lack of compliance with the recommended treatment regimen and may be rectified by recommending that the dosing be done by caregivers. If compliance problems are excluded, the possibility of gonadotropin independent sexual precocity should be reconsidered and appropriate examinations should be conducted. If compliance problems are excluded and if gonadotropin independent sexual precocity is not present, the dose of SYNAREL may be increased to 1800 µg/day administered as 600 µg tid.
Psychiatric events have been reported in patients taking GnRH agonists. Postmarketing reports with this class of drugs includes symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression. Monitor for development or worsening of psychiatric symptoms during treatment with SYNAREL.
Post-marketing reports of convulsions have been observed in patients receiving GnRH agonists. These have included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above.
Severe cutaneous adverse reactions (SCARs) have been reported in patients receiving other GnRH agonists. These reactions include Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), including cases with visceral involvement and/or requiring skin grafts. If a SCAR is suspected, discontinue SYNAREL. Consult with a healthcare provider with expertise in the diagnosis and management of SCARs. If a diagnosis of SCAR is confirmed, permanently discontinue SYNAREL.
Pseudotumor cerebri (idiopathic intracranial hypertension) has been reported in pediatric patients receiving GnRH agonists. Monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea.
Safe use of nafarelin acetate in pregnancy has not been established clinically. Before starting treatment with SYNAREL, pregnancy must be excluded.
When used regularly at the recommended dose, SYNAREL usually inhibits ovulation and stops menstruation. Contraception is not insured, however, by taking SYNAREL, particularly if patients miss successive doses. Therefore, patients should use nonhormonal methods of contraception. Patients should be advised to see their physician if they believe they may be pregnant. If a patient becomes pregnant during treatment, the drug must be discontinued and the patient must be apprised of the potential risk to the fetus.
Clinical Depression
Depression may occur or worsen during treatment with GnRH agonists including SYNAREL 2 mg/mL. Carefully observe women for depression, especially those with a history of depression and consider whether the risks of continuing SYNAREL 2 mg/mL outweigh the benefits. Women with new or worsening depression should be referred to a mental health professional, as appropriate [see Precautions].
Severe cutaneous adverse reactions (SCARs) have been reported in patients receiving other GnRH agonists. These reactions include Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), including cases with visceral involvement and/or requiring skin grafts. If a SCAR is suspected, discontinue SYNAREL. Consult with a healthcare provider with expertise in the diagnosis and management of SCARs. If a diagnosis of SCAR is confirmed, permanently discontinue SYNAREL.
SYNAREL
nafarelin acetate
Nasal Spray
Patient Instructions for Use
Introduction
Your doctor has prescribed SYNAREL Nasal Solution to treat your symptoms of endometriosis. This pamphlet has two purposes:
Please read this pamphlet carefully. If you still have questions after reading it or if you have questions at any time during your treatment with SYNAREL, be sure to check with your doctor.
SYNAREL is used to relieve the symptoms of endometriosis. The lining of the uterus is called the endometrium, and part of it is shed during menses. In endometriosis, endometrial tissue is also found outside the uterus and, like normal endometrial tissue, can bleed during a menstrual cycle. It is, in part, this monthly activity that causes you to have symptoms during your cycle. Most often, this out-of-place endometrial tissue is found around the uterus, ovaries, the intestine or other organs in the pelvis. Although some women with endometriosis have no symptoms, many have problems such as severe menstrual cramps, pain during sexual intercourse, low back pain, and painful bowel movements.
Endometrial tissue is affected by the body's hormones, especially estrogen, which is made by the ovaries. When estrogen levels are low, endometrial tissue shrinks (perhaps even disappears), and symptoms of endometriosis ease. SYNAREL temporarily reduces estrogen in the body and temporarily relieves the symptoms of endometriosis.
Important Information about SYNAREL
You should discuss the possibility of osteoporosis or thinning of the bones with your physician before starting SYNAREL. You should also be aware that repeat treatments are not recommended since they may put you at greater risk of bone thinning, particularly if you have the above conditions.
|
|
Of the 60% of patients who had complete relief of symptoms at the end of treatment, 17% had moderate symptoms at the end of the six month post-treatment period; 33% had mild symptoms; 50% were symptom free; no patient had severe symptoms.
Proper use of SYNAREL for Treatment of Endometriosis
The length of treatment is usually about 6 months, unless your doctor has given you special instructions.
Preparation of the SYNAREL Nasal Spray unit
For use in your nose only.
Before you use SYNAREL nasal spray for the first time, you will need to prime it. This will ensure that you get the right dose of medicine each time you use it.
Important Tips about using SYNAREL
Figure A |
![]() |
To Prime the Pump:
How to use the SYNAREL Nasal Spray unit for the treatment of Endometriosis
| |
| |
Figure G | |
![]() |
|
| |
| |
| |
|
It is important that you clean the spray tip before and after every use. Failure to do this may result in a clogged tip that may cause you to get the wrong dose of medicine.
Important Reminder: Treatment with SYNAREL must be uninterrupted with no missed doses to be effective. Keep out of the reach of children and use carefully as directed. |
Storage Instructions:
|
This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.
LAB-0278-10.0
Revised: November 2025
MEDICATION GUIDE | ||||
What is the most important information I should know about SYNAREL?
Call your child's doctor right away if your child has any new or worsening mental symptoms or problems while taking SYNAREL
Seizures have also happened in people who have not had any of these problems. | ||||
|
| |||
What is SYNAREL? | ||||
Do not give SYNAREL if your child:
| ||||
Before your child takes SYNAREL, tell your doctor about all of your child's medical conditions, including if they:
Tell your doctor about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. | ||||
How should your child take SYNAREL?
| ||||
What should your child avoid while taking SYNAREL?
| ||||
What are the possible side effects of SYNAREL?
| ||||
|
| |||
The side effects of SYNAREL include:
These are not all of the possible side effects of SYNAREL. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||||
General Information about the safe and effective use of SYNAREL. | ||||
What are the ingredients in SYNAREL? | ||||
Instructions for Use
SYNAREL (sin-na-rell)
(nafarelin acetate)
nasal solution
For use in the nose only.
Figure A |
![]() |
Before you use SYNAREL nasal spray for the first time, you will need to prime it. This will make sure that you get the right dose of medicine each time you use it. Priming only needs to be done 1 time, when you start using a new bottle of SYNAREL.
To Prime the Pump:
| |
| |
|
How to use the SYNAREL Nasal Spray for the treatment of Central Precocious Puberty
| |
| |
| |
Put pressure evenly to the "shoulders" and push down quickly and firmly. Pump the sprayer 1 time, at the same time as the child sniffs in gently. Wait about 30 seconds and put one more spray in the same nostril. Repeat this process in the other nostril, for a total of four sprays. If the sprayer fails to deliver the dose, clean the spray tip (See Step 5 Clean the Spray Tip each time before and after using SYNAREL). | |
| |
|
It is important that you clean the spray tip before and after every use. Not doing this may result in a clogged tip that may cause you to get the wrong dose of medicine.
How should I store SYNAREL?
Keep SYNAREL and all medicines out of the reach of children.
For more information call 1-800-438-1985.
This Medication Guide and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Manufactured for: Pfizer Inc., 235 East 42nd Street, New York, NY, 10017
LAB-1049-4.0
Revised: November 2025
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.